NCT00300573View on ClinicalTrials.gov

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

PHASE2TerminatedINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

HIV InfectionsHuman Immunodeficiency Virus

Interventions

DRUG

Dexelvucitabine

nucleoside inhibitor of HIV Reverse Transcriptase

Trial Locations (11)

10018

New York

30309

Atlanta

33317

Plantation

60657

Chicago

90813

Long Beach

97209

Portland

Unknown

Brandon

Fort Lauderdale

Miami

Dallas

00909

San Juan

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY